In this episode of The Leadership Standard podcast, host @Gair Maxwell and guest Blaine Penny discuss his current focus as the CEO of Lumiio Inc.—helping patient organizations, academic research groups, and pharmaceutical companies design world-class digital health programs to accelerate outcomes that impact patient care.
HEAR BLAINE PENNY’S INSIGHT ON:
[2:00] The pivotal moment when Blaine’s son, Evan, faced a life-changing diagnosis of Mitochondrial disease
[7:00] How @MitoCanada—the foundation that has raised over $4 million to advance mitochondrial medicine—came to be
[9:07] The story of Lumiio
[11:59] What exactly is a Mitochondria?
[16:40] How being an ultra-marathon runner has helped Blaine on his leadership pursuits
[23:51] How Blaine defines leadership
[27:01] Blaine’s @Guinness World Records achievements
[31:28] Blaine’s experience as a TEC Canada member
[37:53] Blaine’s personal mission and how it aligns with the causes he is involved in
Blaine’s involvement in rare disease advocacy and research began in 2008 with the tragic onset of mitochondrial disease in his then 4-year-old son, Evan. Today, Evan is a quadriplegic and is unable to talk or eat. No one knows what his future holds, but Blaine is committed to giving his son the best life possible. Motivated to help others going through similar experiences, Blaine co-founded the MitoCanada Foundation in 2009. Since then, they have raised over $4 million to advance mitochondrial medicine and are building a MitoCommunity connecting patients, scientists, clinicians, and industry.
Blaine is a one-of-a-kind personality, who has been recognized for his achievements via Avenue Calgary Magazine’s Top 40 Under 40, is the recipient of 6 Guinness World Records, and is an elite ultra-marathon runner competing on the international stage.
Don’t miss this unforgettable conversation as we celebrate one of the most inspiring people in our world and someone who has made it his life’s work to make humanity better than he found it.
#TECCanada #WorldMitoWeek #LeadershipPodcast